Key result
Low-dose aspirin fails to reduce preeclampsia risk in high-risk pregnant women with PCOS.
Why the study?
Pregnant women with polycystic ovary syndrome have an increased susceptibility to developing preeclampsia, but the efficacy of low-dose aspirin for prevention in this population remains to be investigated.
Does low-dose aspirin prevent preeclampsia in pregnant women with polycystic ovary syndrome at high risk for preeclampsia?
Cohort (n=1,522)
No
Does low-dose aspirin prevent preeclampsia in pregnant women with polycystic ovary syndrome at high risk for preeclampsia?
Relative Risk: 1.33 (95% CI 0.92–1.91)
Absolute Event Rate: 32% vs 21.6%
p-value: p=0.11
Low-dose aspirin did not significantly reduce the risk of preeclampsia in pregnant women with PCOS who are at high risk for the condition.
Does not support routine low-dose aspirin for preeclampsia prophylaxis in PCOS; leaves open.
BACKGROUND: The objective of this study was to investigate the efficacy of low-dose aspirin (LDA) in preventing preeclampsia among pregnant women with polycystic ovary syndrome (PCOS), given the increased susceptibility of this population to preeclampsia development. METHODS: A retrospective cohort study was conducted on pregnant women with PCOS who delivered between January 1, 2018 and February 10, 2024 at our institution. Clinical characteristics and obstetric data were extracted from medical records. Propensity score matching (PSM) was employed to analyze the association between LDA use and PE incidence. RESULTS: The study cohort comprised 1522 pregnant women with PCOS. Among 395 pregnant women identified as high-risk for preeclampsia, 98 were administered LDA for preeclampsia prevention, while 297 did not receive LDA. Following PSM, no statistically significant difference was observed in preeclampsia risk between the LDA and non-LDA groups. Additionally, maternal and neonatal outcomes were comparable between the two groups. CONCLUSIONS: This cohort analysis did not provide sufficient evidence to support the efficacy of LDA in preventing preeclampsia among PCOS patients at high risk for preeclampsia.
No takes yet. Share an insight, caveat, or question.
LUO et al. (2025) conducted a cohort in Polycystic ovary syndrome (PCOS) at high risk for preeclampsia (n=1,522). Low-dose aspirin vs. No low-dose aspirin was evaluated on Incidence of preeclampsia (RR 1.33, 95% CI 0.92-1.91, p=0.11). In pregnant women with polycystic ovary syndrome at high risk for preeclampsia, low-dose aspirin did not significantly reduce the incidence of preeclampsia compared to no aspirin (RR 1.33).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: